Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. November 2017 16:02 ET | Quelle: MyoKardia, Inc.

MyoKardia Reports Third Quarter 2017 Financial Results and Operational Progress

Received FDA Feedback for Mavacamten Registration Program in Symptomatic, Obstructive Hypertrophic Cardiomyopathy MyoKardia to Initiate EXPLORER-HCM as Pivotal Trial in Second Quarter 2018 Company...
01. November 2017 08:00 ET | Quelle: MyoKardia, Inc.

MyoKardia Announces Presentations at 2017 American Heart Association Scientific Sessions

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
31. Oktober 2017 08:00 ET | Quelle: MyoKardia, Inc.

MyoKardia to Present at Two Upcoming Investor Conferences in November

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
26. Oktober 2017 08:00 ET | Quelle: MyoKardia, Inc.

MyoKardia to Announce Third Quarter 2017 Financial Results on Thursday, November 2, 2017

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
27. September 2017 07:30 ET | Quelle: MyoKardia, Inc.

MyoKardia Provides Update on MYK-491 Clinical Progress

Single Ascending Dose Trial in Healthy Volunteers Continues Enrollment in Order to Refine Exposure-Activity-Relationship; Topline Data Expected by Early 2018 Next Trial of MYK-491 in DCM Patients...
18. September 2017 12:45 ET | Quelle: MyoKardia, Inc.

MyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) at the Heart Failure Society of America’s 21st Annual Scientific Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia” or the “Company”), a clinical stage biopharmaceutical company pioneering a precision...
30. August 2017 08:00 ET | Quelle: MyoKardia, Inc.

MyoKardia to Present at Two Upcoming Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
14. August 2017 11:14 ET | Quelle: MyoKardia, Inc.

MyoKardia Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for...
10. August 2017 08:00 ET | Quelle: MyoKardia, Inc.

MyoKardia to Present at 2017 Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
08. August 2017 20:16 ET | Quelle: MyoKardia, Inc.

MyoKardia Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for...

Vorherige Seite